Skip Navigation



ToxSci Advance Access published online on June 30, 2008
Toxicological Sciences, doi:10.1093/toxsci/kfn130
This Article
Right arrow Advance Access manuscript (PDF) Freely available
Right arrow All Versions of this Article:
105/2/384    most recent
kfn130v2
kfn130v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Faiola, B.
Right arrow Articles by Miller, R. T
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Faiola, B.
Right arrow Articles by Miller, R. T
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the Society of Toxicology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

PPAR alpha, more than PPAR delta, mediates the hepatic and skeletal muscle alterations induced by the PPAR agonist GW0742

Brenda Faiola*, J Greg Falls*, Richard A Peterson*, Nancy R Bordelon*,{dagger}, Thomas A Brodie*,{ddagger}, Connie A Cummings*, Elizabeth H Romach* and Richard T Miller*

* Safety Assessment Department, GlaxoSmithKline, Research Triangle Park, NC 27709 USA; Brenda.X.Faiola{at}gsk.com, James.G.Falls{at}gsk.com, Richard.A.Peterson{at}gsk.com, Connie.A.Cummings{at}gsk.com, Beth.H.Romach{at}gsk.com, Richard.T.Miller{at}gsk.com {dagger} Department of Toxicology, Alcon Research Labs, Fort Worth, TX 76134 USA; Nancy.Bordelon{at}AlconLabs.com {ddagger} Safety Assessment Department, GlaxoSmithKline, The Frythe, UK; Brodies3{at}yahoo.com

Corresponding author: Brenda Faiola, PhD, DABT, PO Box 13398, 5 Moore Dr., Research Triangle Park, NC 27709, Phone: 919-483-5075, Fax: 919-483-6858, e-mail: Brenda.x.Faiola{at}gsk.com

Received April 1, 2008; revision received June 16, 2008; accepted June 23, 2008


  Abstract

Therapeutic use of certain peroxisome proliferator-activated receptor (PPAR) alpha agonists (fibrates) for the treatment of dyslipidemia has infrequently been associated with the untoward side effect of myopathy. With interest in PPAR{delta} as a therapeutic target, this study assessed whether a PPAR{delta} agonist induced similar hepatic and skeletal muscle alterations as noted with some fibrates. PPAR{alpha} null (KO) and corresponding wild type (WT) mice were administered toxicological dosages of a potent PPAR{delta} agonist tool ligand (GW0742; which also has weak PPAR{alpha} agonist activity) or a potent PPAR{alpha} agonist (WY–14,643) for 10 days. Increases in liver weights and clinical chemistry indicators of skeletal muscle damage and/or liver injury were more pronounced in WT mice compared with KO mice administered the PPAR{delta} agonist. Likewise, the incidence and severity of skeletal myopathy were greater in WT mice given GW0742 compared with KO mice. Ultrastructural and immunohistochemical analyses revealed significant peroxisome proliferation in muscle and liver of WT mice treated with each agonist; however, KO animals showed little or no evidence of hepatic and muscle peroxisome proliferation. PMP-70 protein expression in liver was consistent with these results. The hepatomegaly, hepatic and skeletal muscle peroxisome proliferation, and skeletal myopathy induced by this PPAR{delta} ligand was predominantly mediated by its cross-activation of PPAR{alpha}, though PPAR{delta} agonism contributed slightly to these effects.

Key Words: Peroxisome proliferator-activated receptor; myopathy; mice.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Lipid Res.Home page
C. L. J. Vrins, A. E. van der Velde, K. van den Oever, J. H. M. Levels, S. Huet, R. P. J. Oude Elferink, F. Kuipers, and A. K. Groen
Peroxisome proliferator-activated receptor delta activation leads to increased transintestinal cholesterol efflux
J. Lipid Res., October 1, 2009; 50(10): 2046 - 2054.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.